Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is April 11, 2021.
All times in Eastern Daylight Time.
-
Samenvatting: Commentaar van de voorzitter van de raad van bestuur van Toshiba op het overnamevoorstel
TOKIO--(BUSINESS WIRE)--Osamu Nagayama, voorzitter van de raad van bestuur van Toshiba Corporation (TOKIO: 6502) heeft commentaar gegeven op het overnamevoorstel van CVC Capital Partners, zoals hie... more » -
“Godzilla vs. Kong” Continues to Dominate the Global Box Office, Amassing Over $350 Million in Its First Weeks
BURBANK, Calif.--(BUSINESS WIRE)--“Godzilla vs. Kong” Continues to Dominate the Global Box Office, Amassing Over $350 Million in Its First Weeks more » -
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of AL... more » -
LG Energy Solution and SK Innovation Reach Agreement to End USITC Trade Secret Dispute and End LitigationWASHINGTON--(BUSINESS WIRE)--LG Energy Solution and SK Innovation announced on April 11th (Korea time) that they have agreed to settle all legal disputes relating to EV batteries in the United Stat... more »
-
Saturday WrestleMania® Sold Out
TAMPA BAY, Fla.--(BUSINESS WIRE)--A sell-out of 25,675 fans attended Night One of WrestleMania at Raymond James Stadium in Tampa Bay, FL with millions more watching at home on Peacock in the U.S. a... more » -
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer more » -
Le test métallurgique de Lomiko au site de La Loutre produit un grade de concentré de 97,8% de carbone et de 93,5% de récupération de graphite
MONTRÉAL--(BUSINESS WIRE)--Lomiko Metals Inc. (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) ("Lomiko" ou la "Société") a le plaisir de publier une mise à jour relative à son projet d'extraction de graphite à... more » -
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Champignon Brands Inc. Investors – SHRMFNEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Champignon Brands Inc. (OTC:... more »
-
AHF Welcomes Biden’s Proposed 15% HUD Budget Increase
LOS ANGELES--(BUSINESS WIRE)--AHF Welcomes Biden’s Proposed 15% HUD Budget Increase more » -
EIG ondertekent infrastructuurovereenkomst van $ 12,4 miljard met Aramco
WASHINGTON--(BUSINESS WIRE)--EIG, een toonaangevende institutionele belegger in de wereldwijde energiesector en een van 's werelds vooraanstaande investeerders in infrastructuur, heeft vandaag aang... more » -
Voluntary Recall of Hostess® SnoBalls® Due to Undeclared Allergen
LENEXA, Kan.--(BUSINESS WIRE)--Hostess Brands, LLC (“Hostess Brands”) has become aware that certain Hostess® SnoBalls® were inadvertently manufactured in the packaging for Hostess® Chocolate CupCak... more » -
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma ModelROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a n... more »
-
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 MeetingROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target... more »
-
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluati... more » -
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meetin... more »